9:20 am Chair’s Opening Remarks

9:30 am Reserved for Spotlight Partner

  • Grace Bandong Business Unit Manager, Contaminants, Eurofins Food Chemistry Testing

Mid to Late Clinical Development (PHASE 2/3)

9:40 am Multi-Format Session: Pitfalls to Avoid in Late-Stage Cannabinoid Clinical Trials – a Post-Mortem of Cannabinoid Clinical Trials

Synopsis

  • 20 minute presentation
  • Roundtable discussion on tears, tantrums, frustrations of in-human clinical cannabinoid trials, followed by panel discussion

10:40 am Reserved for Exhibition Partner

11:10 am Morning Break & Speed Networking

11:54 am

Novel Cannabinoid Compounds

11:55 am Faah Inhibitors: The Innocent Pay for the Guilty

Synopsis

  • Discuss past research conducted on FAAH inhibitors by major players and small biotech companies
  • Address concerns over safety
  • Look at why so many companies are rediscovering this molecule now

Drug Delivery Technologies

12:25 pm Delivery Platforms to Produce Better Therapeutics

  • Sean Hall Chief Executive Officer, Medlab Clinical

Synopsis

  • Explore how cannabinoids, whilst potentiated to hold therapeutic benefit and administered in varying ways with both short and long-term side effects, more is not always better
  • Evaluate how for cannabinoids to truly become a medicine, patient risk needs to be minimized and delivery platforms have the potential to mitigate this risk
  • Understand NanoCelle® Medlab’s proprietary, patented delivery platform and how it will be used as an example of low efficacious dose with minimal side effects in over 1100 Australian patients

Effective Targeting

11:55 am Target Identification/Validation with ECS Drug

  • Duncan Mackie Director - Pharmacology & Experimental Therapeutics, MedPharm Holdings

Synopsis

  • In the context of Medpharm’s current research into degenerative disease, discuss key ideas involved in the
    phase 1 study design process
  • Consider key target identification principles

Biomarker Identification & Validation

12:25 pm A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder

  • Itzhak Kurek Chief Executive Officer & Co-Founder, Cannformatics

Synopsis

  • Examine how successful autism spectrum disorder (ASD) treatment is challenging due to subjective evaluation of changes in social interaction, language and communication ability, and repetitive behaviors, observed by clinician and family members of the individual with ASD
  • Study metabolic biomarkers and how they are an attractive method to quantify and personalize medical cannabis (MC) treatment for individuals with ASD
  • Investigate how such biomarkers also present an opportunity to understand the underlying mechanism of action (MOA) of MC treatment in individuals with ASD
  • Inspect how Cannabis-Responsive™ biomarkers in saliva provide a scientifically validated technology to objectively quantify the impact of MC and can indicate the MOA in children with ASD treated under physician supervision

12:55 pm Lunch Break & Poster Session

2:30 pm Complex Chemically Active Transdermal Emulsion System Systemically Delivering CBD & THC Into Healthy Volunteers

Synopsis

  • Take a look at novel chemically active transdermal emulsion system used for systemic delivery of therapeutic concentrations of CBD and THC
  • Examine the structure of CTA Health Canada bioavailability study in healthy volunteers conducted in Dec/Jan
  • Review of in vivo patient bioavailability data including blood concentration curves for the delivery of CBD and THC over a 12-hour period

3:00 pm Cannabinoid Side Effects: A Downer in Search of Mitigation

Synopsis

  • Identify side effects of cannabinoid use clinically
  • Discuss how to address side effects of cannabinoid use clinically

Combing RWE & Clinical Research to Identify Therapeutic Opportunity

2:30 pm Aggregating Large-Scale RWE to Reveal Health Effects of Major & Minor Phytocannabinoids

  • Jeff Chen Founder & Director, Radicle Sciences

Synopsis

  • Analyze the known effects of minor phytocannabinoids from randomized controlled trials published in peerreviewed journals
  • Understand how pragmatic trials can be used to study phytocannabinoids cheaper and faster
  • Explore the known effects of major and minor phytocannabinoids from unpublished RWE

Establishing an IP Strategy

3:00 pm Designing a Robust IP Strategy

Synopsis

  • Hear perspectives on IP strategy and enforcement from key opinion leaders at the heart of the cannabis and cannabinoid field
  • Understand the IP lifecycle, and how work at one stage can influence another. For example, what your team can do during prosecution to prepare a company for litigation

3:30 pm Afternoon Break

4:00 pm Therapeutic Potential of Cannabinoids in Combination Cancer Therapy

Synopsis

  • Understand how the current known therapeutic potential of cannabinoids as antiemetic, antianorexic and antiseizure remedies can be useful in a drug combo for cancer
  • Discuss what studies are needed for this potential to be capitalized on

Funding for Cannabinoid Research

4:00 pm Accessing Investment to Further Cannabinoid Research

Synopsis

  • Discuss how to attract funds from cannabis-focused investment funds, as well as traditional mainstream investment banks
  • Identify current trends in stock values of medcann/ cannabinoid pharmaceuticals

4:30 pm Chair’s Closing Remarks

4:45 pm End of Day Two & Conference